Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.
Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal, lung ...
Kids with polyarticular-course juvenile idiopathic arthritis (JIA) who received a second tumor necrosis factor (TNF) inhibitor after failing one initially did just as well as those who changed to a ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...
FDA Issues Reminder on Risk for Serious Fungal Infections With TNF-alpha Blockers, Including Simponi
May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...
WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...
Almost two thirds (64%) of patients with psoriatic arthritis (PsA) who were receiving tumor necrosis factor alpha (TNFα) inhibitors achieved a state of minimal disease activity (MDA), according to a ...
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results